Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Summary
The Next GEN Act amends the Social Security Act to lengthen the market exclusivity for engineered cyclic peptide medicines from seven to eleven years when they are considered single‑source drugs under the Medicare drug price negotiation program. It also provides a specific definition of “engineered cyclic peptide.” The change aims to give developers more time to recoup investment while still allowing Medicare to negotiate prices for other drugs.
AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.
Track this bill
Get real-time alerts when HR 8857 changes status, plus AI-powered summaries and stage predictions.
Sign up free